Carbamoyl phosphate synthetase
Carbamoyl phosphate synthetase (CPS) is an essential enzyme involved in the biosynthesis of both pyrimidines and arginine. It plays a crucial role in the urea cycle, which is responsible for the detoxification of ammonia in mammals. CPS catalyzes the formation of carbamoyl phosphate, a key intermediate in these metabolic pathways.
Structure[edit]
CPS is a large, multi-domain enzyme that exists in two isoforms: CPS I and CPS II. CPS I is primarily found in the liver, while CPS II is present in other tissues. Both isoforms share a similar overall structure, consisting of multiple subunits that come together to form a functional enzyme.
CPS I is composed of three subunits: a small regulatory subunit, a large catalytic subunit, and an additional protein called N-acetylglutamate synthase (NAGS). NAGS is responsible for the synthesis of N-acetylglutamate (NAG), an allosteric activator of CPS I. The catalytic subunit contains the active site where the carbamoyl phosphate synthesis takes place.
CPS II, on the other hand, is a multifunctional enzyme that consists of a single polypeptide chain with three distinct domains: the glutamine amidotransferase (GAT), the carbamoyl phosphate synthetase (CPS), and the aspartate transcarbamoylase (ATC) domains. These domains work together to catalyze the sequential reactions leading to the synthesis of carbamoyl phosphate.
Mechanism of Action[edit]
The synthesis of carbamoyl phosphate by CPS involves the utilization of two substrates: bicarbonate and glutamine. The reaction occurs in multiple steps, with each step being catalyzed by a specific domain of CPS II.
First, the GAT domain of CPS II hydrolyzes glutamine to produce glutamate and ammonia. The ammonia released in this step is then utilized in the subsequent reaction. The CPS domain of CPS II combines the ammonia with bicarbonate and ATP to form carbamate, which is subsequently phosphorylated to generate carbamoyl phosphate. Finally, the ATC domain of CPS II transfers the carbamoyl group from carbamoyl phosphate to aspartate, leading to the formation of N-carbamoyl-L-aspartate.
Regulation[edit]
The activity of CPS is tightly regulated to maintain the balance of pyrimidine and arginine synthesis, as well as the detoxification of ammonia. CPS I is allosterically activated by N-acetylglutamate (NAG), which is synthesized by NAGS in response to the levels of arginine. NAG binds to CPS I and enhances its catalytic activity.
CPS II, on the other hand, is regulated by feedback inhibition. The end product of the pyrimidine biosynthesis pathway, cytidine triphosphate (CTP), acts as an allosteric inhibitor of CPS II. When the cellular levels of CTP are high, CPS II activity is reduced, preventing the overproduction of pyrimidines.
Clinical Significance[edit]
Mutations in the genes encoding CPS I and CPS II can lead to various metabolic disorders. Deficiencies in CPS I result in hyperammonemia, a condition characterized by the accumulation of ammonia in the blood. This can lead to severe neurological symptoms and can be life-threatening if not managed properly.
CPS II deficiencies are rare but can cause orotic aciduria, a disorder characterized by the excessive excretion of orotic acid in the urine. This condition is associated with impaired pyrimidine synthesis and can lead to growth retardation and anemia.
See Also[edit]
References[edit]
-
Carbamoyl phosphate synthetase
-
Structure of carbamoyl phosphate synthetase
-
Crystal structure of carbamoyl phosphate synthetase
-
Carbamoyl phosphate synthetase complex
-
Enzyme structure of carbamoyl phosphate synthetase
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian